CRISPR enhances cancer immunotherapy

(Washington University School of Medicine) The FDA recently approved the first cellular immunotherapies to treat certain blood cancers. But so far, these T cell immunotherapies can't be used if the T cells themselves are cancerous. Such 'CAR-T' cells kill each other because they resemble one another so closely. Scientists at Washington University School of Medicine in St. Louis now have used the gene-editing technology CRISPR to engineer human T cells that can attack human T cell cancers without...